Ikena Oncology Statistics
Share Statistics
Ikena Oncology has 41.89M
shares outstanding. The number of shares has increased by -16.58%
in one year.
| Shares Outstanding | 41.89M |
| Shares Change (YoY) | -16.58% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 65.71% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 128.85K, so 0.27% of the outstanding
shares have been sold short.
| Short Interest | 128.85K |
| Short % of Shares Out | 0.27% |
| Short % of Float | 0.3% |
| Short Ratio (days to cover) | 1.44 |
Valuation Ratios
The PE ratio is -1.61 and the forward
PE ratio is -1.47.
Ikena Oncology's PEG ratio is
0.04.
| PE Ratio | -1.61 |
| Forward PE | -1.47 |
| PS Ratio | 0 |
| Forward PS | 2.6 |
| PB Ratio | 0.63 |
| P/FCF Ratio | -1.72 |
| PEG Ratio | 0.04 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Ikena Oncology.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.8,
with a Debt / Equity ratio of 0.06.
| Current Ratio | 11.8 |
| Quick Ratio | 11.8 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | -0.15 |
| Debt / FCF | -0.16 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-4,923,400 |
| Employee Count | 10 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 152K |
| Effective Tax Rate | -0.31% |
Stock Price Statistics
The stock price has increased by -12.78% in the
last 52 weeks. The beta is 0.48, so Ikena Oncology's
price volatility has been higher than the market average.
| Beta | 0.48 |
| 52-Week Price Change | -12.78% |
| 50-Day Moving Average | 1.24 |
| 200-Day Moving Average | 1.53 |
| Relative Strength Index (RSI) | 47 |
| Average Volume (20 Days) | 93,141 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -58.97M |
| Net Income | -49.23M |
| EBITDA | -48.59M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.02 |
Full Income StatementBalance Sheet
The company has 39.39M in cash and 7.52M in
debt, giving a net cash position of 31.87M.
| Cash & Cash Equivalents | 39.39M |
| Total Debt | 7.52M |
| Net Cash | 31.87M |
| Retained Earnings | -331.62M |
| Total Assets | 141.51M |
| Working Capital | 116.39M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -46M
and capital expenditures 0, giving a free cash flow of -46M.
| Operating Cash Flow | -46M |
| Capital Expenditures | n/a |
| Free Cash Flow | -46M |
| FCF Per Share | -0.95 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
